Sleep Disorders Predict Frailty Progression in Type 2 Diabetes Mellitus: Findings from a Cohort of 20,562 Patients

Jui Wang; Szu-Ying Lee; Ginger Chu; Chia-Ter Chao; Kuo-Liong Chien; Jenq-Wen Huang

doi:10.4093/dmj.2025.0905

Articles

Page Path: HOME > Diabetes Metab J > Volume 50(1); 2026 > Article

Letter Sleep Disorders Predict Frailty Progression in Type 2 Diabetes Mellitus: Findings from a Cohort of 20,562 Patients: Jui Wang^1,2*, Szu-Ying Lee^3*, Ginger Chu^4,5,6, Chia-Ter Chao^7,8,9,10, Kuo-Liong Chien¹, Jenq-Wen Huang⁷; Diabetes & Metabolism Journal 2026;50(1):199-202.
DOI: https://doi.org/10.4093/dmj.2025.0905
Published online: January 1, 2026

579 Views
25 Download

¹Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan

²Health Data Research Center, National Taiwan University, Taipei, Taiwan

³Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County, Taiwan

⁴School of Nursing and Midwifery, College of Health Medicine and Wellbeing, University of Newcastle, Callaghan, Australia

⁵Asthma and Breathing Research Program, Hunter Medical Research Institute, Callaghan, Australia

⁶Nephrology Department, John Hunter Hospital, New Lambton Heights, Australia

⁷Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

⁸Graduate Institute of Toxicology, National Taiwan University College of Medicine, Taipei, Taiwan

⁹Graduate Institute of Medical Education and Bioethics, National Taiwan University College of Medicine, Taipei, Taiwan

¹⁰Division of Nephrology, Department of Internal Medicine, Min-Sheng General Hospital, Taoyuan City, Taiwan

Corresponding author: Chia-Ter Chao

Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, NO.7, Zhong-Shan South Road, Zhong-Zheng district, Taipei, Taiwan E-mail: b88401084@ntu.edu.tw

* Jui Wang and Szu-Ying Lee contributed equally to this study as first authors.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

Full Article

Download PDF

NOTES
REFERENCES
About this article

The global incidence and public health burden of type 2 diabetes mellitus (T2DM) have risen steadily over recent decades. T2DM accelerates functional decline and premature aging. Furthermore, T2DM is a major risk factor for frailty. Diabetes and frailty share overlapping pathophysiological mechanisms, including chronic inflammation, insulin resistance, malnutrition, and hormonal dysregulation, while frailty itself may elevate the risk of developing diabetes [1]. Identifying frailty in patients with T2DM is therefore essential. Despite frailty’s clinical importance, the determinants of its development and progression in T2DM remain incompletely understood. Prior studies have implicated certain medication uses as potential contributors to incident frailty in this population [2], but few address risk factors for worsening frailty [3].

Sleep disorders are common in diabetes, with insomnia affecting up to 39% of patients, 4-fold higher than that in the general population [4]. We hypothesized that sleep disorders significantly increase the risk of worsening frailty among patients with T2DM, and assembled a large hospital-based cohort to examine this association. Adults aged ≥40 years with T2DM were retrospectively identified from the National Taiwan University Hospital integrated Medical Database between 2008 and 2016. The study had received approval (No. 201708098RIND). The exposure of interest was physician-diagnosed sleep disorder at baseline, identified using International Classification of Diseases (ICD) codes validated in prior research [5]. The spectrum of sleep disorders identified included insomnia, hypersomnia, parasomnia, sleep related breathing or movement disorders, circadian rhythm disorders, and substance-induced sleep disorders, according to the updated classification of the International Classification of Sleep Disorders. The primary outcome was worsening frailty, defined as an increase of ≥1 Fatigue, Resistance, Ambulation, Illnesses, and Loss of Weight (FRAIL) scale score relative to baseline assessment results, as adopted by others [3]. The five components of FRAIL scale were retrospectively coded from clinical data, diagnoses, procedural details/records, an approach partially adopted by others [6]. The validity of our operationalization approach has been shown to be fair, with results exhibiting good correlation with index-based findings [3]. For multivariate analysis, we adopted four strategies; model 1 included demographic (age, sex) and physical indices (body mass index), comorbidities (hypertension, hyperlipidemia, atrial fibrillation, cerebrovascular disease, myocardial infarction, acute coronary syndrome, heart failure, peripheral vascular disease, chronic kidney disease, chronic liver disease, malignancy, and chronic obstructive pulmonary disease) and medications (glucose-lowering drugs, anti-hypertensive and anti-hyperlipidemic drugs, anti-coagulants, anti-platelet agents, and anti-inflammatory drugs). Model 2 included model 1 covariates and laboratory data (glycemic indices, lipid profile, creatinine and estimated glomerular filtration rate [eGFR]). Models 3 and 4 further accounted for competing risk of mortality and baseline frailty, respectively.

A total of 82,208 adults with T2DM were screened (Fig. 1A), with 20,562 (25.0%) included in final analyses. The mean age was 64.2±10.9 years, with 44.8% female, mean glycosylated hemoglobin 7.1%±1.3%, and a mean eGFR of 73.1±26.5 mL/min/1.73 m². Around 19.2% of patients had a sleep disorder at baseline. After a median 3.94 years (interquartile range, 1.8 to 7.1), 5,698 patients (27.7%) developed worsening frailty. Kaplan-Meier analysis demonstrated a significantly higher cumulative incidence of frailty progression in patients with sleep disorders (log-rank P<0.01) (Fig. 1B). Following multivariable adjustment, this association remained significant (model 1: hazard ratio [HR], 1.13; 95% confidence interval [CI], 1.06 to 1.21; model 2: HR, 1.15; 95% CI, 1.08 to 1.23) (Fig. 1C). The results were unchanged when death (model 3) (Fig. 1C) or baseline frailty (model 4) (Fig. 1C) was considered. Insomnia/hypersomnia alone also conferred elevated risk (HR, 1.14; 95% CI, 1.06 to 1.22). Subgroup analyses (Fig. 1D) showed that the association between sleep disorders and frailty progression was evident among patients of different age strata, sex, and without or with chronic kidney disease, and the adjustment for baseline frailty intensified the association strengths. Glycemic control status did not modify the association between sleep disorders and risk of worsening frailty.

Previous research on sleep and frailty in diabetes has been limited to cross-sectional designs, which preclude causal inferences [7]. Our study adds to this literature by providing longitudinal evidence from a large, well-characterized cohort, using a broad definition of sleep disorders that extends beyond sleep duration or subjective quality. Importantly, our results demonstrate that the effect is not confined to older adults but is relevant across the adult diabetes mellitus (DM) population, providing a glimpse into the degree of risk elevation. The mechanisms linking sleep disorders to frailty progression are likely multifactorial. Sleep disturbances can exacerbate cardiovascular morbidity, depression, and poor nutritional status, all established contributors to frailty [7]. Sleep disorders are also associated with sarcopenia [8], which represents a core pathway to functional decline. Additionally, sleep disruption may accelerate cognitive impairment, a recognized risk factor for frailty propagation. These overlapping biological and behavioral mechanisms provide a plausible basis for the associations observed.

Our subgroup findings (Fig. 1D) warrant further discussion. A previous study disclosed that predictors of impaired physical function in patients with DM changed with age; poor sleep quality correlated with decreasing walking distance only in those age <58 years but not older ones [9]. The stronger association in middle-aged adults is consistent with these data that sleep quality predicts physical decline more prominently at younger ages, whereas in older individuals, other factors such as sarcopenia or nutritional compromise may overshadow the impact of sleep disruption. Similarly, the absence of an association in patients with impaired kidney function may reflect the dominant influence of uremic toxins and chronic inflammation on frailty in this population [10]. These observations highlight the heterogeneous impact of sleep disorders and suggest that targeted screening strategies may be most beneficial in specific patient groups.

The clinical implications of our findings are substantial. Sleep hygiene and disorder management are increasingly recognized as integral components of chronic disease care. Non-pharmacological interventions, such as bedtime relaxation techniques, exercise, and structured sleep education, have shown promise in improving sleep quality. Other strategies, like bedroom environment re-arrangement or sleep pattern adaptation, require more evidence to support. Optimizing sleep through personalized interventions may also improve glycemic control stability, reduce hypoglycemia risk, and ultimately lead to lower long-term likelihood of worsening frailty.

Our study has several strengths, including the large sample size, longitudinal design, and comprehensive adjustment for confounding variables. Nevertheless, limitations should be acknowledged. First, frailty was assessed solely using the FRAIL scale only, though this tool has been validated in the diabetes population [3]. Second, we lacked direct measures of muscle mass and nutritional status. Third, residual confounding and selection bias cannot be excluded due to the retrospective design. Enrollees were younger and had a higher prevalence of comorbidities than the excluded ones, but four out of the five FRAIL components of the former group at baseline did not differ from those of the excluded patients, except illness. Our findings are more applicable to those with T2DM and high comorbidity burden, receiving hospital-based care. Fourth, we did not document sleep-managing medications in this study.

In conclusion, in this large, longitudinal cohort of patients with T2DM, baseline sleep disorders were independently associated with a higher risk of frailty progression. Incorporating routine sleep assessment into diabetes care and developing targeted interventions to improve sleep quality may offer new opportunities to favorably alter frailty courses in this vulnerable population.

The Institutional Review Board of National Taiwan University Hospital has approved the parent protocol of the main study (No. 201708098RIND). Informed consent was waived due to the anonymized nature of retrospective data retrieval from the Integrated Medical Database.

NOTES

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

FUNDING

This work was supported by National Taiwan University Hospital (114-N0054) and National Science and Technology Council (NSTC 112-2314-B-002-232-MY3).

ACKNOWLEDGMENTS

The raw data for conducting this analysis are unavailable according to the regulatory policy of National Taiwan University Hospital Integrated Medical Database.

Fig. 1

(A) Study participant selection algorithm. (B) Kaplan-Meier event-free analyses according to sleep disorder presence or not. (C) Results of multivariate Cox proportional hazard regression analyses, including models 1 to 3. (D) Subgroup analysis results. DM, diabetes mellitus; NTUH, National Taiwan University Hospital; P, population; PY, person-year; HR, hazard ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate.

REFERENCES

1. Sinclair AJ, Rodriguez-Manas L. Diabetes and frailty: two converging conditions? Can J Diabetes 2016;40:77-83.Article PubMed
2. Lee SY, Wang J, Tsai HB, Chao CT, Chien KL, Huang JW. Muscle relaxant use and the associated risk of incident frailty in patients with diabetic kidney disease: a longitudinal cohort study. Ther Adv Drug Saf 2021;12:20420986211014639.Article PubMed PMC PDF
3. Wang J, Lee SY, Chao CT, Huang JW, Chien KL. The impact of blood pressure lowering agents on the risk of worsening frailty among patients with diabetes mellitus: a cohort study. NPJ Aging 2024;10:44.Article PubMed PMC PDF
4. Schipper SB, Van Veen MM, Elders PJ, van Straten A, Van Der Werf YD, Knutson KL, et al. Sleep disorders in people with type 2 diabetes and associated health outcomes: a review of the literature. Diabetologia 2021;64:2367-77.Article PubMed PMC PDF
5. Long JJ, Chen Y, Kim B, Bae S, Li Y, Orandi BJ, et al. Sleep disorders and dementia risk in older patients with kidney failure: a retrospective cohort study. Clin J Am Soc Nephrol 2024;19:1301-9.PubMed PMC
6. Chao CT, Wang J, Chien KL. Both pre-frailty and frailty increase healthcare utilization and adverse health outcomes in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2018;17:130.PubMed PMC
7. Lyu Q, Guan CX, Kong LN, Zhu JL. Prevalence and risk factors of cognitive frailty in community-dwelling older adults with diabetes: a systematic review and meta-analysis. Diabet Med 2023;40:e14935.Article PubMed PDF
8. Ida S, Kaneko R, Nagata H, Noguchi Y, Araki Y, Nakai M, et al. Association between sarcopenia and sleep disorder in older patients with diabetes. Geriatr Gerontol Int 2019;19:399-403.Article PubMed PDF
9. Fritschi C, Bronas UG, Park CG, Collins EG, Quinn L. Early declines in physical function among aging adults with type 2 diabetes. J Diabetes Complications 2017;31:347-52.Article PubMed PMC
10. Chao CT, Lin SH. Uremic toxins and frailty in patients with chronic kidney disease: a molecular insight. Int J Mol Sci 2021;22:6270.Article PubMed PMC

Figure & Data

References

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite this Article

Cite this Article: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Sleep Disorders Predict Frailty Progression in Type 2 Diabetes Mellitus: Findings from a Cohort of 20,562 Patients

Diabetes Metab J. 2026;50(1):199-202. Published online January 1, 2026

DOI: https://doi.org/10.4093/dmj.2025.0905

XML Download

Figure

Sleep Disorders Predict Frailty Progression in Type 2 Diabetes Mellitus: Findings from a Cohort of 20,562 Patients

Fig. 1 (A) Study participant selection algorithm. (B) Kaplan-Meier event-free analyses according to sleep disorder presence or not. (C) Results of multivariate Cox proportional hazard regression analyses, including models 1 to 3. (D) Subgroup analysis results. DM, diabetes mellitus; NTUH, National Taiwan University Hospital; P, population; PY, person-year; HR, hazard ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate.

Fig. 1

Sleep Disorders Predict Frailty Progression in Type 2 Diabetes Mellitus: Findings from a Cohort of 20,562 Patients

About this article

Wang J, Lee SY, Chu G, Chao CT, Chien KL, Huang JW. Sleep Disorders Predict Frailty Progression in Type 2 Diabetes Mellitus: Findings from a Cohort of 20,562 Patients. Diabetes Metab J. 2026;50(1):199-202.

DOI: https://doi.org/10.4093/dmj.2025.0905.

Download citation ↓